CG Reports Q3 Operating Profit Expected to Surge 93% YoY as Non-Respiratory Diagnostics Drive Growth
According to Daol Investment Securities on October 8, CG projects Q3 operating profit of 18.6 billion won, a 93% increase year-over-year, with revenue of 129.6 billion won up 14%. Non-respiratory diagnostic products, including HPV and STI testing, are expected to reach 67.3 billion won in Q3
GateNews·10-07 23:38
